ACET
Adicet Bio, Inc.
Price Chart
Latest Quote
$7.26
-0.89 (-10.92%)
Current Price
| Previous Close | $8.15 |
| Open | $8.05 |
| Day High | $8.06 |
| Day Low | $7.26 |
| Volume | 85,546 |
Stock Information
| Shares Outstanding | 9.35M |
| Total Debt | $13.90M |
| Cash Equivalents | $137.59M |
| Net Income | $-108.83M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $67.87M |
| EPS (TTM) | $-13.87 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-55.83M |
| Income | $-108.83M |
| Book/sh | $14.59 |
| Cash/sh | $14.72 |
| Employees | 102 |
Financial Ratios
| Quick Ratio | 7.52 |
| Current Ratio | 7.66 |
| Debt/Eq | 9.92 |
Returns & Margins
| ROA | -39.44% |
| ROE | -72.19% |
Ownership
| Insider Ownership | 0.92% |
| Institutional Ownership | 63.61% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.73 |
| P/B | 0.50 |
Analyst Data
| Recommendation | none |
| Target Price | $34.83 |
Technical Indicators
| SMA20 | $8.12 |
| SMA50 | $7.74 |
| SMA200 | $9.42 |
| RSI | 45.95 |
| ATR | 0.5953 |
| Shares Float | 5.83M |
| Short Float | 6.31% |
| Short Ratio | 5.23 |
| Rel Volume | 0.73 |
Performance History
| Week | -22.02% |
| Month | -15.09% |
| Quarter | -0.41% |
| 6 Months | -15.50% |
| YTD | -17.69% |
| Year | -42.64% |
| 3 Years | -91.72% |
| 5 Years | -96.62% |
| 10 Years | -99.62% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $7.26 | 85,546 |
| 2026-06-04 | $8.15 | 63,300 |
| 2026-06-03 | $7.83 | 113,700 |
| 2026-06-02 | $8.11 | 170,800 |
| 2026-06-01 | $8.78 | 66,800 |
| 2026-05-29 | $9.31 | 203,700 |
| 2026-05-28 | $8.64 | 114,300 |
| 2026-05-27 | $8.50 | 100,400 |
| 2026-05-26 | $8.33 | 90,200 |
| 2026-05-22 | $8.30 | 92,000 |
| 2026-05-21 | $7.89 | 105,800 |
| 2026-05-20 | $7.76 | 154,100 |
| 2026-05-19 | $7.25 | 171,400 |
| 2026-05-18 | $7.50 | 100,900 |
| 2026-05-15 | $7.68 | 138,800 |
| 2026-05-14 | $8.41 | 155,200 |
| 2026-05-13 | $8.07 | 45,700 |
| 2026-05-12 | $7.95 | 63,500 |
| 2026-05-11 | $8.17 | 198,700 |
| 2026-05-08 | $8.55 | 96,800 |
| 2026-05-07 | $8.32 | 60,100 |
| 2026-05-06 | $8.55 | 113,000 |
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
đ° Latest News
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
MarketBeat âĸ 2026-06-04T18:04:52Z
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Zacks âĸ 2026-05-28T13:40:01Z
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
Zacks âĸ 2026-05-25T13:55:03Z
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Zacks âĸ 2026-03-24T16:00:04Z
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
Zacks âĸ 2025-10-07T13:40:02Z
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2025-09-30T16:00:03Z
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
Insider Monkey âĸ 2025-08-11T13:46:17Z
Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001
Clinical Trials Arena âĸ 2025-07-25T11:27:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $24,990,000 |
| Operating Revenue | $0 | $0 | $0 | $24,990,000 |
| Expenses | ||||
| Interest Expense | $36,000 | $4,000 | $25,000 | $80,000 |
| Total Expenses | $122,114,000 | $127,615,000 | $132,576,000 | $97,541,000 |
| Other Income Expense | $-430,000 | $-217,000 | $-20,035,000 | $-919,000 |
| Other Non Operating Income Expenses | $-430,000 | $-217,000 | $-573,000 | $-919,000 |
| Net Non Operating Interest Income Expense | $5,741,000 | $10,710,000 | $9,953,000 | $3,680,000 |
| Interest Expense Non Operating | $36,000 | $4,000 | $25,000 | $80,000 |
| Operating Expense | $122,114,000 | $127,615,000 | $132,576,000 | $97,541,000 |
| General And Administrative Expense | $22,987,000 | $28,292,000 | $26,533,000 | $26,295,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-116,803,000 | $-117,122,000 | $-142,658,000 | $-69,790,000 |
| Net Interest Income | $5,741,000 | $10,710,000 | $9,953,000 | $3,680,000 |
| Interest Income | $5,777,000 | $10,714,000 | $9,978,000 | $3,760,000 |
| Normalized Income | $-116,803,000 | $-117,122,000 | $-123,196,000 | $-69,790,000 |
| Net Income From Continuing And Discontinued Operation | $-116,803,000 | $-117,122,000 | $-142,658,000 | $-69,790,000 |
| Total Operating Income As Reported | $-122,114,000 | $-127,615,000 | $-152,038,000 | $-72,551,000 |
| Net Income Common Stockholders | $-116,803,000 | $-117,122,000 | $-142,658,000 | $-69,790,000 |
| Net Income | $-116,803,000 | $-117,122,000 | $-142,658,000 | $-69,790,000 |
| Net Income Including Noncontrolling Interests | $-116,803,000 | $-117,122,000 | $-142,658,000 | $-69,790,000 |
| Net Income Continuous Operations | $-116,803,000 | $-117,122,000 | $-142,658,000 | $-69,790,000 |
| Pretax Income | $-116,803,000 | $-117,122,000 | $-142,658,000 | $-69,790,000 |
| Interest Income Non Operating | $5,777,000 | $10,714,000 | $9,978,000 | $3,760,000 |
| Operating Income | $-122,114,000 | $-127,615,000 | $-132,576,000 | $-72,551,000 |
| Special Income Charges | - | $0 | $-19,462,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-16.95 | $-21.28 | $-52.96 | $-27.20 |
| Basic EPS | $-16.95 | $-21.28 | $-52.96 | $-27.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-110,386,000 | $-110,650,000 | $-117,073,000 | $-67,135,000 |
| Reconciled Depreciation | $6,381,000 | $6,468,000 | $6,098,000 | $2,575,000 |
| EBITDA (Bullshit earnings) | $-110,386,000 | $-110,650,000 | $-136,535,000 | $-67,135,000 |
| EBIT | $-116,767,000 | $-117,118,000 | $-142,633,000 | $-69,710,000 |
| Diluted Average Shares | $6,891,336 | $5,491,652 | $2,690,150 | $2,567,517 |
| Basic Average Shares | $6,891,336 | $5,491,652 | $2,690,150 | $2,567,517 |
| Diluted NI Availto Com Stockholders | $-116,803,000 | $-117,122,000 | $-142,658,000 | $-69,790,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Research And Development | $99,127,000 | $99,323,000 | $106,043,000 | $71,246,000 |
| Selling General And Administration | $22,987,000 | $28,292,000 | $26,533,000 | $26,295,000 |
| Other Gand A | $22,987,000 | $28,292,000 | $26,533,000 | $26,295,000 |
| Total Unusual Items | - | $0 | $-19,462,000 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-19,462,000 | $0 |
| Impairment Of Capital Assets | - | $0 | $19,462,000 | $0 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $159,210,000 | $186,609,000 | $170,175,000 | $272,876,000 |
| Total Assets | $192,355,000 | $220,219,000 | $207,295,000 | $330,690,000 |
| Total Non Current Assets | $31,429,000 | $40,083,000 | $45,023,000 | $69,652,000 |
| Other Non Current Assets | $2,948,000 | $3,331,000 | $822,000 | $1,211,000 |
| Current Assets | $160,926,000 | $180,136,000 | $162,272,000 | $261,038,000 |
| Other Current Assets | $320,000 | $737,000 | $457,000 | $336,000 |
| Prepaid Assets | $1,734,000 | $2,999,000 | $2,104,000 | $2,611,000 |
| Receivables | $342,000 | $97,000 | $0 | $435,000 |
| Accrued Interest Receivable | $342,000 | $97,000 | $0 | $435,000 |
| Cash Cash Equivalents And Short Term Investments | $158,530,000 | $176,303,000 | $159,711,000 | $257,656,000 |
| Cash And Cash Equivalents | $38,918,000 | $56,495,000 | $159,711,000 | $257,656,000 |
| Goodwill And Other Intangible Assets | - | - | $0 | $19,462,000 |
| Accounts Receivable | - | - | - | $0 |
| Investmentin Financial Assets | - | - | - | - |
| Taxes Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $14,738,000 | $17,234,000 | $20,924,000 | $21,023,000 |
| Long Term Debt And Capital Lease Obligation | $11,552,000 | $14,102,000 | $17,703,000 | $18,531,000 |
| Current Debt And Capital Lease Obligation | $3,186,000 | $3,132,000 | $3,221,000 | $2,492,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $33,145,000 | $33,610,000 | $37,120,000 | $38,352,000 |
| Total Non Current Liabilities Net Minority Interest | $11,614,000 | $14,218,000 | $17,833,000 | $18,645,000 |
| Other Non Current Liabilities | $62,000 | $116,000 | $130,000 | $114,000 |
| Current Liabilities | $21,531,000 | $19,392,000 | $19,287,000 | $19,707,000 |
| Payables And Accrued Expenses | $12,713,000 | $9,148,000 | $9,552,000 | $11,512,000 |
| Payables | $4,739,000 | $4,830,000 | $2,625,000 | $4,404,000 |
| Accounts Payable | $4,739,000 | $4,830,000 | $2,625,000 | $4,404,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Non Current Deferred Liabilities | - | - | - | - |
| Non Current Deferred Taxes Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $159,210,000 | $186,609,000 | $170,175,000 | $292,338,000 |
| Total Equity Gross Minority Interest | $159,210,000 | $186,609,000 | $170,175,000 | $292,338,000 |
| Stockholders Equity | $159,210,000 | $186,609,000 | $170,175,000 | $292,338,000 |
| Gains Losses Not Affecting Retained Earnings | $102,000 | $16,000 | $0 | $0 |
| Other Equity Adjustments | $102,000 | $16,000 | - | - |
| Retained Earnings | $-614,697,000 | $-497,894,000 | $-380,772,000 | $-238,114,000 |
| Other | ||||
| Ordinary Shares Number | $9,586,770 | $5,160,573 | $2,704,399 | $2,684,676 |
| Share Issued | $9,586,770 | $5,160,573 | $2,704,399 | $2,684,676 |
| Tangible Book Value | $159,210,000 | $186,609,000 | $170,175,000 | $272,876,000 |
| Invested Capital | $159,210,000 | $186,609,000 | $170,175,000 | $292,338,000 |
| Working Capital | $139,395,000 | $160,744,000 | $142,985,000 | $241,331,000 |
| Capital Lease Obligations | $14,738,000 | $17,234,000 | $20,924,000 | $21,023,000 |
| Total Capitalization | $159,210,000 | $186,609,000 | $170,175,000 | $292,338,000 |
| Additional Paid In Capital | $773,795,000 | $684,482,000 | $550,943,000 | $530,448,000 |
| Capital Stock | $10,000 | $5,000 | $4,000 | $4,000 |
| Common Stock | $10,000 | $5,000 | $4,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $11,552,000 | $14,102,000 | $17,703,000 | $18,531,000 |
| Current Capital Lease Obligation | $3,186,000 | $3,132,000 | $3,221,000 | $2,492,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,632,000 | $7,112,000 | $6,514,000 | $5,703,000 |
| Current Accrued Expenses | $7,974,000 | $4,318,000 | $6,927,000 | $7,108,000 |
| Net PPE | $28,481,000 | $36,752,000 | $44,201,000 | $48,979,000 |
| Accumulated Depreciation | $-27,387,000 | $-21,315,000 | $-14,847,000 | $-8,753,000 |
| Gross PPE | $55,868,000 | $58,067,000 | $59,048,000 | $57,732,000 |
| Leases | $28,422,000 | $28,228,000 | $26,643,000 | $19,959,000 |
| Construction In Progress | $198,000 | $198,000 | $265,000 | $9,292,000 |
| Other Properties | $25,674,000 | $28,087,000 | $30,589,000 | $27,772,000 |
| Machinery Furniture Equipment | $1,574,000 | $1,554,000 | $1,551,000 | $709,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $119,612,000 | $119,808,000 | $0 | - |
| Goodwill | - | - | $0 | $19,462,000 |
| Current Deferred Revenue | - | - | - | $0 |
| Investments And Advances | - | - | - | - |
| Held To Maturity Securities | - | - | - | - |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-96,984,000 | $-93,496,000 | $-98,181,000 | $-61,547,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-95,246,000 | $-92,378,000 | $-93,717,000 | $-44,765,000 |
| Cash Flow From Continuing Operating Activities | $-95,246,000 | $-92,378,000 | $-93,717,000 | $-44,765,000 |
| Operating Gains Losses | $103,000 | - | $-4,000 | $54,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,738,000 | $-1,118,000 | $-4,464,000 | $-16,782,000 |
| Investing Cash Flow | $2,393,000 | $-119,242,000 | $-4,464,000 | $-16,782,000 |
| Cash Flow From Continuing Investing Activities | $2,393,000 | $-119,242,000 | $-4,464,000 | $-16,782,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $75,172,000 | $110,918,000 | $0 | $43,360,000 |
| Financing Cash Flow | $75,245,000 | $111,307,000 | $236,000 | $41,509,000 |
| Cash Flow From Continuing Financing Activities | $75,245,000 | $111,307,000 | $236,000 | $41,509,000 |
| Net Other Financing Charges | $-104,000 | $-141,000 | $-150,000 | $-3,598,000 |
| Net Common Stock Issuance | $75,172,000 | $110,918,000 | $0 | $43,360,000 |
| Common Stock Issuance | $75,172,000 | $110,918,000 | $0 | $43,360,000 |
| Other | ||||
| Repayment Of Debt | $-150,000 | $0 | - | - |
| End Cash Position | $41,790,000 | $59,398,000 | $159,711,000 | $257,656,000 |
| Beginning Cash Position | $59,398,000 | $159,711,000 | $257,656,000 | $277,694,000 |
| Changes In Cash | $-17,608,000 | $-100,313,000 | $-97,945,000 | $-20,038,000 |
| Proceeds From Stock Option Exercised | $327,000 | $530,000 | $386,000 | $1,747,000 |
| Net Issuance Payments Of Debt | $-150,000 | $0 | - | - |
| Net Long Term Debt Issuance | $-150,000 | $0 | - | - |
| Long Term Debt Payments | $-150,000 | $0 | - | - |
| Net Investment Purchase And Sale | $4,131,000 | $-118,124,000 | $0 | $0 |
| Sale Of Investment | $145,000,000 | $11,000,000 | $0 | $0 |
| Purchase Of Investment | $-140,869,000 | $-129,124,000 | $0 | - |
| Net PPE Purchase And Sale | $-1,738,000 | $-1,118,000 | $-4,464,000 | $-16,782,000 |
| Purchase Of PPE | $-1,738,000 | $-1,118,000 | $-4,464,000 | $-16,782,000 |
| Change In Working Capital | $1,473,000 | $-5,525,000 | $252,000 | $2,744,000 |
| Change In Other Current Liabilities | $-3,449,000 | $-3,691,000 | $-99,000 | $-2,264,000 |
| Change In Other Current Assets | $308,000 | $353,000 | $358,000 | $929,000 |
| Change In Payables And Accrued Expense | $2,933,000 | $-916,000 | $-933,000 | $7,541,000 |
| Change In Accrued Expense | $1,904,000 | $-2,022,000 | $750,000 | $5,831,000 |
| Change In Payable | $1,029,000 | $1,106,000 | $-1,683,000 | $1,710,000 |
| Change In Account Payable | $1,029,000 | $1,106,000 | $-1,683,000 | $1,710,000 |
| Change In Prepaid Assets | $1,681,000 | $-1,271,000 | $926,000 | $1,343,000 |
| Other Non Cash Items | $3,426,000 | $3,236,000 | $2,874,000 | $2,526,000 |
| Stock Based Compensation | $14,267,000 | $22,233,000 | $20,259,000 | $17,126,000 |
| Amortization Of Securities | $-4,093,000 | $-1,668,000 | $0 | $0 |
| Depreciation Amortization Depletion | $6,381,000 | $6,468,000 | $6,098,000 | $2,575,000 |
| Depreciation And Amortization | $6,381,000 | $6,468,000 | $6,098,000 | $2,575,000 |
| Gain Loss On Sale Of PPE | $103,000 | $0 | $-4,000 | $54,000 |
| Net Income From Continuing Operations | $-116,803,000 | $-117,122,000 | $-142,658,000 | $-69,790,000 |
| Asset Impairment Charge | - | $0 | $19,462,000 | $0 |
| Income Tax Paid Supplemental Data | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | $-4,805,000 |
| Change In Receivables | - | - | - | $185,000 |
| Changes In Account Receivables | - | - | - | $185,000 |
Fetched: 2026-05-30